Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

Neurology

Volumn 91, Issue 24, 2018, Pages E2265-E2275

  Papp, Viktoria ^a   Illes, Zsolt ^b,c   Magyari, Melinda ^e,f   Koch Henriksen, Nils ^f,g   Kant, Matthias ^h   Pfleger, Claudia Christina ⁱ   Roemer, Shanu Faerch ^j   Jensen, Michael Broksgaard ^k   Petersen, Annett Evelyn ^l   Nielsen, Helle Hvilsted ^b,c   Rosendahl, Lene ^m   Mezei, Zsolt ⁱ   Christensen, Tove ^g   Svendsen, Kristina ^a   Jensen, Poul Erik Hyldgaard ^e   Lydolph, Magnus Christian ⁿ   Heegaard, Niels ⁿ   Frederiksen, Jette Lautrup ^o   Sellebjerg, Finn ^e   Stenager, Egon ^d,h   Petersen, Thor ^a   more..

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Rigshospitalet   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

^h Sonderborg Hospital   (Denmark)

ⁱ AALBORG UNIVERSITY HOSPITAL   (Denmark)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k HILLERØD HOSPITAL   (Denmark)

^l ESBJERG HOSPITAL   (Denmark)

^m Central Region Denmark   (Denmark)

ⁿ STATENS SERUM INSTITUT   (Denmark)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY;

ADULT; ARTICLE; CAUCASIAN; DENMARK; DISEASE REGISTRY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; ADOLESCENT; AGED; CHILD; IMMUNOASSAY; PATIENT SELECTION; POPULATION RISK; RISK FACTOR; TREND STUDY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DENMARK; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85058607500     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000006645     Document Type: Article

References (35)

1. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immu-noreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130:1194-1205.
2. Lennon PVA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
4. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-1174.
5. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
6. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177-189.
7. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016;13:279.
8. Bukhari W, Prain KM, Waters P, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88:632-638.
9. Sepúlveda M, Aldea M, Escudero D, et al. Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler Epub 2017 Oct 1.
10. Hor JY, Lim TT, Chia YK, et al. Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence. Mult Scler Relat Disord 2018;19:20-24.
11. Dale GH, Svendsen KB, Gjelstrup MC, et al. Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. Acta Neurol Scand 2018;137: 582-588.
12. Eskandarieh S, Nedjat S, Azimi AR, Moghadasi AN, Sahraian MA. Neuromyelitis optica spectrum disorders in Iran. Mult Scler Relat Disord 2017;18:209-212.
13. Houzen H, Kondo K, Niino M, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology 2017;89:1995-2001.
14. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39:30-33.
15. Brønnum-Hansen H, Koch-Henriksen N, Stenager E. The Danish Multiple Sclerosis Registry. Scand J Public Health 2011;39:62-64.
16. Koch-Henriksen N, Magyari M, Laursen B. Registers of multiple sclerosis in Denmark. Acta Neurol Scand 2015;132:4-10.
17. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016;87:1005-1015.
18. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuro-inflamm 2015;2:e89.
19. Chapman D. Some Properties of the Hypergeometric Distribution with Applications to Zoological Censuses. Berkeley: University of California Press; 1951:131-160.
20. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-1849.
21. Statistikbanken. Available at: statbank.dk/statbank5a/default.asp?w=12. Accessed December 1, 2017.
22. Ng R, Bernatsky S, Rahme E. Observation period effects on estimation of systemic lupus erythematosus incidence and prevalence in Quebec. J Rheumatol 2013;40:1334-1336.
23. Aboul-Enein F, Seifert-Held T, Mader S, et al. Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One 2013;8:e79649.
24. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589-1595.
25. Cossburn M, Tackley G, Baker K, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012;19:655-659.
26. Jacob A, Panicker J, Lythgoe D, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 2013;260: 2134-2137.
27. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016;79:775-783.
28. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009;256:35-44.
29. Miyamoto K, Fujihara K, Kira JI, et al. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry 2018;89:667-668.
30. Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014;20:1651-1653.
31. Kashipazha D, Mohammadianinejad SE, Majdinasab N, Azizi M, Jafari M. A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iran J Neurol 2015;14:204-210.
32. Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z. An epidemiological study of neuromyelitis optica in Isfahan. Mult Scler 2014;20: 1920-1922.
33. Houzen H, Niino M, Hirotani M, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 2012;323: 117-122.
34. Uzawa A, Mori M, Uchida T, Masuda H, Ohtani R, Kuwabara S. Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Mult Scler 2016;22:1371-1375.
35. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.